ADXNAddex Therapeutics Ltd.

Nasdaq addextherapeutics.com


$ 8.79 $ 0.68 (8.38 %)    

Thursday, 02-May-2024 12:25:22 EDT
QQQ $ 426.96 $ 1.72 (0.4 %)
DIA $ 382.16 $ 0.64 (0.17 %)
SPY $ 504.97 $ 0.56 (0.11 %)
TLT $ 88.96 $ 0.74 (0.84 %)
GLD $ 213.40 $ 0.94 (0.44 %)
$ 8.1101
$ 8.79
$ 0.00 x 0
$ 0.00 x 0
$ 8.79 - $ 8.79
$ 5.00 - $ 27.90
15,613
na
1.02B
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 johnson--johnson-partnered-addex-therapeutics-epilepsy-candidate-fails-mid-stage-study-stock-tanks

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex T...

 addex-therapeutics-announces-lack-of-statistical-significance-in-adx71149-phase-2-epilepsy-study

Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small m...

 earnings-scheduled-for-april-18-2024

Companies Reporting Before The Bell • Addex Therapeutics (NASDAQ:ADXN) is estimated to report earnings for its fourth quarter.

 addex-therapeutics-fy23-eps-chf-014-up-from-chf-046-yoy-income-chf-165m-up-from-chf-145m-yoy

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, r...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 why-macatawa-bank-shares-are-trading-higher-by-around-37-here-are-20-stocks-moving-premarket

Shares of Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corpora...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION